TAVR Outcomes: The Milan Experience

Two competing devices for transcatheter aortic valve replacement produced good overall outcomes in a study of 305 patients from the Milan registry, Dr. Gill Louise Buchanan and associates reported at Transcatheter Cardiovascular Therapeutics 2011.

The combined 30-day mortality for the devices – Edwards Lifesciences’ Sapien valve (ESV) and Medtronic’s CoreValve ReValving System – was 4.7%. The myocardial infarction rate was 1.3% and the rate of stroke was 1.0%, said Dr. Buchanan of the interventional cardiology unit at San Raffaele Scientific Institute in Milan, and her associates.

"There was no difference in device success (92.5% overall), combined safety end point at 30 days (61.8%) or combined efficacy end point (72.0%) at 1-year follow-up," between the two valves, but there were significant differences in conduction disturbance and/or arrhythmia occurrence and the need for pacemaker (see graph, below), the investigators said.

Note: Based on data from 305 patients treated from November 2007 to April 2011.

Source: Dr. Gill Louise Buchanan and associates

Two competing devices for transcatheter aortic valve replacement produced good overall outcomes in a study of 305 patients from the Milan registry, Dr. Gill Louise Buchanan and associates reported at Transcatheter Cardiovascular Therapeutics 2011.

The combined 30-day mortality for the devices – Edwards Lifesciences’ Sapien valve (ESV) and Medtronic’s CoreValve ReValving System – was 4.7%. The myocardial infarction rate was 1.3% and the rate of stroke was 1.0%, said Dr. Buchanan of the interventional cardiology unit at San Raffaele Scientific Institute in Milan, and her associates.

"There was no difference in device success (92.5% overall), combined safety end point at 30 days (61.8%) or combined efficacy end point (72.0%) at 1-year follow-up," between the two valves, but there were significant differences in conduction disturbance and/or arrhythmia occurrence and the need for pacemaker (see graph, below), the investigators said.

Note: Based on data from 305 patients treated from November 2007 to April 2011.

Source: Dr. Gill Louise Buchanan and associates

Two competing devices for transcatheter aortic valve replacement produced good overall outcomes in a study of 305 patients from the Milan registry, Dr. Gill Louise Buchanan and associates reported at Transcatheter Cardiovascular Therapeutics 2011.

The combined 30-day mortality for the devices – Edwards Lifesciences’ Sapien valve (ESV) and Medtronic’s CoreValve ReValving System – was 4.7%. The myocardial infarction rate was 1.3% and the rate of stroke was 1.0%, said Dr. Buchanan of the interventional cardiology unit at San Raffaele Scientific Institute in Milan, and her associates.

"There was no difference in device success (92.5% overall), combined safety end point at 30 days (61.8%) or combined efficacy end point (72.0%) at 1-year follow-up," between the two valves, but there were significant differences in conduction disturbance and/or arrhythmia occurrence and the need for pacemaker (see graph, below), the investigators said.

Note: Based on data from 305 patients treated from November 2007 to April 2011.

Source: Dr. Gill Louise Buchanan and associates